Affibodies, hydrogels containing affibodies, and uses thereof

Patent metadata

Field	Value
Publication number	US-2025382361-A1
Application number	US-202519238192-A
Country	US
Kind code	A1
Filing date	Jun 13, 2025
Priority date	Jun 13, 2024
Publication date	Dec 18, 2025
Grant date	—

Abstract

Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (K D ). Also provided are methods of using the affibodies to treat a disease, wound, injury, or cancer.

First claim

We claim:

1 . A composition comprising:
a hydrogel; one or more proteins; and one or more affibodies; wherein the one or more affibodies are specific for the one or more proteins.

2 . The composition of claim 1 , wherein the one or more proteins are non-covalently bound to the one or more affibodies.

3 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

4 . The composition of claim 1 , wherein the one or more proteins comprise one or more of bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF).

5 . The composition of claim 4 , wherein the one or more proteins further comprise one or more of collagen I, collagen III, and monocyte chemoattractant protein-1 (MCP-1).

6 . The composition of claim 1 , wherein the hydrogel comprises at least two different affibodies, wherein the at least two affibodies are specific for at least two of BMP-2, VEGF, FGF-2, PDGF, GM-CSF, IL-4, and GDNF.

7 . The composition of claim 1 , wherein the hydrogel comprises affibodies specific for:
VEGF, FGF-2, and PDGF; FGF-2, and PDGF; GM-CSF; GDNF; BMP-2; BMP-2 and IL-4; VEGF, FGF-2, PDGF, and BMP-2; PDGF and VEGF; GM-CSF and IL-4; GM-CSF, IL-4 and MCP-1; or GM-CSF, IL-4, and BMP-2.

8 . The composition of claim 1 , wherein the one or more affibodies comprise one or more of SEQ ID NOS: 1-63, 65-74, and 77-80, and optionally an additional C-terminal Cys, Lys, Tyr, Try, or Phe; or
wherein the one or more affibodies comprise one or more of SEQ ID NOS: 1, 2, 3, 12, 13, 14, 20, 21, 22, 42, 43, 44, 57, 58, 59, 60, 61, 62, 63, 77, 78, 79, and 80, and optionally an additional C-terminal Cys, Lys, Tyr, Try, or Phe.

9 . The composition of claim 1 , wherein the hydrogel comprises hyaluronic acid (HA), polyethylene glycol (PEG), PEG-Maleimide (PEG-Mal), modified hyaluronic acid, thiolated poly(E-caprolactone) (PCL-SH), thiolated poly(lactide-co-glycolide) (PLGA-SH), thiolated silk-firbroin, modified gelatin (methacrylate (GelMA), oxidized gelatin, gelatin norbornene), thiolated poly(syulfobetaine), thiolated poly(carboxybetaine), thiolated chitosan, collagen, or combinations thereof.

10 . The composition of claim 1 , wherein the one or more affibodies include at least three different affibodies specific for one or more of BMP-2, VEGF, FGF-2, PDGF, GM-CSF, IL-4, and GDNF, wherein the at least three different affibodies each have different dissociation constants (K D ) for the protein.

11 . A method of treating a subject, comprising
administering an effective amount of the composition of claim 1 to the subject, thereby treating the subject.

12 . The method of claim 11 , wherein the subject has a bone injury, and the composition comprises one or more BMP-2 affibodies, one or more IL-4 affibodies, and/or one or more GM-CSF affibodies; or
wherein the subject has a vascular disease, and the composition comprises one or more VEGF affibodies, one or more FGF-2 affibodies, one or more PDGF affibodies, and/or one or more GM-CSF affibodies; or wherein the subject has a neurological disease or injury, and the composition comprises one or more GDNF affibodies.

13 . The method of claim 12 , wherein the vascular disease is a wound, peripheral artery disease, diabetic ulcer, or critical limb ischemia, and/or
wherein the composition comprises one or more FGF-2 affibodies, and one or more PDGF affibodies, optionally wherein the one or more FGF-2 affibodies are medium affinity affibodies, and the one or more PDGF affibodies are high affinity affibodies, optionally wherein the one or more FGF-2 affibodies comprises SEQ ID NO: 43, and the one or more PDGF affibodies comprises SEQ ID NO: 59.

14 . The method of claim 11 , wherein the administering comprises administration to the site of injury, systemic administration, surgical administration, or injection.

15 . An isolated affibody,
comprising at least 90% sequence identity to any one of SEQ ID NOS: 1-63, 65-74, and 77-80; comprising at least 90% sequence identity to any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe; comprising any one of SEQ ID NOS: 1-63, 65-74, and 77-80; comprising any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe; consisting of any one of SEQ ID NOS: 1-63, 65-74 and 77-80; or consisting of any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe.

16 . The isolated affibody of claim 15 , wherein the affibody is 58, 59, 60, or 65 amino acids in length, and/or wherein the affibody comprises 1, 2, 3, 4, 5 or 6 conservative amino acid substitutions.

17 . A method of treating a subject, comprising administering an effective amount of the isolated affibody of claim 15 to the subject, thereby treating the subject.

18 . The method of claim 17 , wherein the subject has a cancer, or a retinal or choroidal vascular disease, and the isolated affibody comprises one or more PDGF and/or VEGF affibodies.

19 . The method of claim 17 , wherein the administration comprises systemic or local administration.

20 . The method of claim 19 , wherein the administration comprises injection to the site of cancer or to the eye.

21 . A composition comprising:
(a) a hydrogel; and (b) one or more affibodies, comprising at least 90% sequence identity to any one of SEQ ID NOS: 1-63, 65-74, and 77-80; comprising at least 90% sequence identity to any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe; comprising any one of SEQ ID NOS: 1-63, 65-74, and 77-80; comprising any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe; consisting of any one of SEQ ID NOS: 1-63, 65-74 and 77-80; or consisting of any one of SEQ ID NOS: 1-63, 65-74, and 77-80 and further comprising a C-terminal Cys, Lys, Tyr, Try, or Phe.

22 . A composition comprising:
a hydrogel; one or more affibodies specific to FGF-2; and one or more affibodies specific to PDGF.

23 . The composition of claim 22 , further comprising VEGF, FGF-2, and PDGF.

Assignees

• Univ Oregon

Inventors

• Hettiaratchi Marian
• Svendsen Justin
• Dorogin Jonathan
• Galindo Alycia

Classifications

• C07K2317/73

  Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title

• C07K16/22 Primary

  against growth factors {; against growth regulators} · CPC title